Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

BACKGROUND & AIMS: We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. METHODS: A multicenter, retrospective, observational cohort study (May 2014 to December 2017) of ulcerative colitis patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Gastroenterol Hepatol
Main Authors: Lukin, Dana, Faleck, David, Xu, Ronghui, Zhang, Yiran, Weiss, Aaron, Aniwan, Satimai, Kadire, Siri, Tran, Gloria, Rahal, Mahmoud, Winters, Adam, Chablaney, Shreya, Koliani-Pace, Jenna L., Meserve, Joseph, Campbell, James P., Kochhar, Gursimran, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Boland, Brigid, Singh, Siddharth, Hirten, Robert, Ungaro, Ryan, Lasch, Karen, Shmidt, Eugenia, Jairath, Vipul, Hudesman, David, Chang, Shannon, Swaminath, Arun, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026779/
https://ncbi.nlm.nih.gov/pubmed/33039584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2020.10.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados